Format

Send to

Choose Destination
Radiother Oncol. 2005 Jul;76(1):1-3.

The alpha/beta ratio for prostate cancer: what is it, really?

Author information

1
Department of Human Oncology, University of Wisconsin Medical School, WI 53792, USA. bentzen@humonc.wisc.edu

Abstract

Two recent studies of fractionated external beam radiotherapy in early prostate cancer provide outcome data that allow a statistical estimation of the alpha/beta-ratio of the linear-quadratic model when combined with clinical data on the steepness of the dose-response curve. Results of the large randomized PR5 trial by the Ontario Clinical Oncology Group/National Cancer Institute of Canada yield an estimate of alpha/beta at 1.12 Gy with 95% confidence interval (-3.3, 5.6) Gy. A non-randomized study by Valdagni and colleagues of hyper-fractionation delivered BID versus conventional fractionation yields an alpha/beta-estimate of 8.3 Gy with 95% confidence interval (0.7, 16) Gy. Thus, the confidence interval of this latter study cannot exclude even very low values of alpha/beta. Furthermore, this point estimate may be an over-estimate if incomplete repair plays a role in the BID group of the Italian study. Taken together, the outcomes of these two studies still favor a high fractionation sensitivity of prostate cancer.

PMID:
15990189
DOI:
10.1016/j.radonc.2005.06.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center